FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 174.28

Change

+0.73 (+0.42)%

Market Cap

N/A

Volume

0.10M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-16 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.56 (+0.40%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

+0.35 (+0.52%)

USD 2.62B
FXH First Trust Health Care AlphaD..

+0.50 (+0.47%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+1.22 (+1.34%)

USD 0.21B
IDNA iShares Genomics Immunology an..

-0.02 (-0.09%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.17 (-0.56%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.41 (+0.43%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.13 (+0.45%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.19 (+0.32%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.42 (-1.89%)

USD 8.55M

ETFs Containing FBT

FHM:CA 0.00 % 0.78 %

N/A

N/A
FBT:CA First Trust NYSE Arca Bio.. 0.00 % 0.00 %

+0.15 (+0.48%)

CAD 1.83M

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.86% 90% A- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.86% 90% A- 84% B
Trailing 12 Months  
Capital Gain 15.65% 100% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.65% 100% F 60% D-
Trailing 5 Years  
Capital Gain 14.62% 38% F 59% D-
Dividend Return 1.46% 37% F 4% F
Total Return 16.08% 38% F 45% F
Average Annual (5 Year Horizon)  
Capital Gain 1.26% 33% F 38% F
Dividend Return 1.59% 33% F 29% F
Total Return 0.33% 42% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 12.22% 86% B+ 74% C
Risk Adjusted Return 13.05% 38% F 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.